COVID-19, a resilient pandemic
Abstract
The COVID-19 pandemic that currently affects the entire world has exposed the general population to information generated by different sectors of society such as social networks, traditional media such as radio, television, newspapers and, interestingly, the information produced by scientists who study disease. This bombardment of information (true or false) can be immense, overwhelming and it is necessary to provide the reading public with clear messages, with truthful information that positively contributes to overcoming the current pandemic. One of the most important issues that generate uncertainty and concern in the population is that of vaccines, which is undoubtedly influencing the containment of the pandemic. In this sense, this document presents scientific data on the immunology of vaccines, its role in infection control over the years; the pathogenic characteristics of SARSCoV2 related to the immune response; and recent epidemiological data on the safety and efficacy of the most widely used vaccines as of press time. The evidence presented aims to clarify the important role that vaccines have in infection control and particularly in the current COVID-19 pandemic.
Downloads
References
2. Stolle LB, Nalamasu R, Pergolizzi J V., Varrassi G, Magnusson P, LeQuang JA, et al. Fact vs Fallacy: The Anti-Vaccine Discussion Reloaded. Adv Ther [Internet]. 2020 Nov 1 [cited 2021 Nov 15];37(11):4481–90. Available from: https://pubmed.ncbi.nlm.nih.gov/32965654/
3. Chung YH, Beiss V, Fiering SN, Steinmetz NF. Covid-19 vaccine frontrunners and their nanotechnology design. ACS Nano [Internet]. 2020 Oct 27 [cited 2021 Nov 15];14(10):12522–37. Available from: https://pubmed.ncbi.nlm.nih.gov/33034449/
4. World Health Organization. Vacuna antitetánica Documento de posición de la OMS. 2008.
5. Centros para el Control y la Prevención de las Enfermedades CDC. Eficacia de la vacuna: ¿Qué tan bien funcionan las vacunas contra la influenza? | CDC [Internet]. [cited 2021 Nov 15]. Available from: https://espanol.cdc.gov/flu/vaccines-work/vaccineeffect.htm
6. Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol [Internet]. 2020 Nov 1 [cited 2021 Nov 15];85. Available from: https://pubmed.ncbi.nlm.nih.gov/32798769/
7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 31 [cited 2021 Nov 15];383(27):2603–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33301246/
8. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–79.
9. Lau EH, Hui DS, Tsang OT, Chan W-H, Kwan MY, Chiu SS, et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine [Internet]. 2021 Nov [cited 2021 Nov 15];41:101174. Available from: https://pubmed.ncbi.nlm.nih.gov/34746725/
10. Sagili Anthony DP, Sivakumar K, Venugopal P, Sriram DK, George M. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Clin Drug Investig [Internet]. 2021 Jun 1 [cited 2021 Nov 15];41(6):499–509. Available from: https://pubmed.ncbi.nlm.nih.gov/33754328/
11. Ita K. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. Arch Med Res [Internet]. 2021 Jan 1 [cited 2021 Nov 15];52(1):15–24. Available from: https://pubmed.ncbi.nlm.nih.gov/32950264/
12. Datosmacro.com. Chile - COVID-19 - Vacunas administradas 2021 | datosmacro.com [Internet]. [cited 2021 Nov 15]. Available from: https://datosmacro.expansion.com/otros/coronavirus-vacuna/chile
13. Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and safety of covid-19 vaccines in phase iii trials: A meta-analysis. Vaccines [Internet]. 2021 Jun 1 [cited 2021 Nov 15];9(6). Available from: https://pubmed.ncbi.nlm.nih.gov/34206032/
14. Centros para el Control y la Prevención de las Enfermedades CDC. COVID-19 Vaccine Effectiveness Research | CDC [Internet]. [cited 2021 Nov 15]. Available from: https://www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html
15. CDC. CDC COVID Data Tracker [Internet]. [cited 2021 Nov 15]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
16. Peghin M, Bouza E, Fabris M, De Martino M, Palese A, Bontempo G, et al. Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19. Eur J Clin Microbiol Infect Dis [Internet]. 2021 [cited 2021 Nov 15];40(12). Available from: https://pubmed.ncbi.nlm.nih.gov/34378086/
17. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021 Mar 27;397(10280):1204–12.
18. Report O. OKLAHOMA COVID-19 WEEKLY REPORT Weekly Epidemiology and Surveillance Report PURPOSE To provide up-to-date weekly epidemiological data on COVID-19 in Oklahoma.
19. Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. The Lancet Microbe [Internet]. 2021 Oct [cited 2021 Nov 15];0(0). Available from: http://www.thelancet.com/article/S2666524721002196/fulltext
Copyright (c) 2021 Rural Family Practice
This work is licensed under a Creative Commons Attribution 4.0 International License.
